Several cardiovascular effects have been attributed to carfilzomib in the recent literature. These side effects must be recognized promptly
Abstract
Several cardiovascular effects have been attributed to carfilzomib in the recent literature. These side effects must be recognized promptly by treating physicians and pharmacists. Special attention is required in patients with pre-existing cardiac conditions, liver function abnormalities and/or advanced age. This is the first report of a severe left atrial enlargement due to carfilzomib use in the setting of multiple myeloma. This condition improved dramatically seven months after cessation of carfilzomib. The authors discuss further various cardiac and vascular abnormalities linked with carfilzomib in the medical literature. Prompt withdrawal of this agent is essential in these cases as it may prevent dismal outcomes.
PMID: 30636528 [PubMed - indexed for MEDLINE]
15:18
Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
15:18
In reply to this message
pubmed: caandvteortroorpul
ASCO updated recommendations for preventing and treating VTE in adults with cancer.
Related Articles
ASCO updated recommendations for preventing and treating VTE in adults with cancer.
Ann Intern Med. 2020 Jan 21;172(2):JC2
Authors: Stockler MR
PMID: 31958816 [PubMed - in process]
15:18
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
15:18
In reply to this message
pubmed: caandvteortroorpul
How I treat cancer-associated thrombosis.
Related Articles
How I treat cancer-associated thrombosis.
ESMO Open. 2020 Jan;5(1):
Authors: Moik F, Pabinger I, Ay C
Comments
Post a Comment
اكتب تعليق حول الموضوع